231 related articles for article (PubMed ID: 26522388)
21. A Non-Canonical Calmodulin Target Motif Comprising a Polybasic Region and Lipidated Terminal Residue Regulates Localization.
Grant BMM; Enomoto M; Ikura M; Marshall CB
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32326637
[TBL] [Abstract][Full Text] [Related]
22. Prenylation is not necessary for endogenous Ras activation in non-malignant cells.
Khwaja A; Dockrell ME; Hendry BM; Sharpe CC
J Cell Biochem; 2006 Feb; 97(2):412-22. PubMed ID: 16187291
[TBL] [Abstract][Full Text] [Related]
23. Multivalent assembly of KRAS with the RAS-binding and cysteine-rich domains of CRAF on the membrane.
Fang Z; Lee KY; Huo KG; Gasmi-Seabrook G; Zheng L; Moghal N; Tsao MS; Ikura M; Marshall CB
Proc Natl Acad Sci U S A; 2020 Jun; 117(22):12101-12108. PubMed ID: 32414921
[TBL] [Abstract][Full Text] [Related]
24. GTP loading of farnesylated p21Ras by insulin at the plasma membrane.
Goalstone M; Leitner JW; Draznin B
Biochem Biophys Res Commun; 1997 Oct; 239(1):42-5. PubMed ID: 9345266
[TBL] [Abstract][Full Text] [Related]
25. Exploring CRD mobility during RAS/RAF engagement at the membrane.
Nguyen K; López CA; Neale C; Van QN; Carpenter TS; Di Natale F; Travers T; Tran TH; Chan AH; Bhatia H; Frank PH; Tonelli M; Zhang X; Gulten G; Reddy T; Burns V; Oppelstrup T; Hengartner N; Simanshu DK; Bremer PT; Chen D; Glosli JN; Shrestha R; Turbyville T; Streitz FH; Nissley DV; Ingólfsson HI; Stephen AG; Lightstone FC; Gnanakaran S
Biophys J; 2022 Oct; 121(19):3630-3650. PubMed ID: 35778842
[TBL] [Abstract][Full Text] [Related]
26. Quantitative biophysical analysis defines key components modulating recruitment of the GTPase KRAS to the plasma membrane.
Lakshman B; Messing S; Schmid EM; Clogston JD; Gillette WK; Esposito D; Kessing B; Fletcher DA; Nissley DV; McCormick F; Stephen AG; Jean-Francois FL
J Biol Chem; 2019 Feb; 294(6):2193-2207. PubMed ID: 30559287
[TBL] [Abstract][Full Text] [Related]
27. Structural and biophysical properties of farnesylated KRas interacting with the chaperone SmgGDS-558.
Michalak DJ; Unger B; Lorimer E; Grishaev A; Williams CL; Heinrich F; Lösche M
Biophys J; 2022 Oct; 121(19):3684-3697. PubMed ID: 35614853
[TBL] [Abstract][Full Text] [Related]
28. Precise characterization of KRAS4b proteoforms in human colorectal cells and tumors reveals mutation/modification cross-talk.
Ntai I; Fornelli L; DeHart CJ; Hutton JE; Doubleday PF; LeDuc RD; van Nispen AJ; Fellers RT; Whiteley G; Boja ES; Rodriguez H; Kelleher NL
Proc Natl Acad Sci U S A; 2018 Apr; 115(16):4140-4145. PubMed ID: 29610327
[TBL] [Abstract][Full Text] [Related]
29. Farnesylation of Ras is important for the interaction with phosphoinositide 3-kinase gamma.
Rubio I; Wittig U; Meyer C; Heinze R; Kadereit D; Waldmann H; Downward J; Wetzker R
Eur J Biochem; 1999 Nov; 266(1):70-82. PubMed ID: 10542052
[TBL] [Abstract][Full Text] [Related]
30. Interaction of KRas4B protein with C6-ceramide containing lipid model membranes.
Li L; Dwivedi M; Erwin N; Möbitz S; Nussbaumer P; Winter R
Biochim Biophys Acta Biomembr; 2018 May; 1860(5):1008-1014. PubMed ID: 29357287
[TBL] [Abstract][Full Text] [Related]
31. Is Nanoclustering essential for all oncogenic KRas pathways? Can it explain why wild-type KRas can inhibit its oncogenic variant?
Nussinov R; Tsai CJ; Jang H
Semin Cancer Biol; 2019 Feb; 54():114-120. PubMed ID: 29307569
[TBL] [Abstract][Full Text] [Related]
32. The quaternary assembly of KRas4B with Raf-1 at the membrane.
Jang H; Zhang M; Nussinov R
Comput Struct Biotechnol J; 2020; 18():737-748. PubMed ID: 32257057
[TBL] [Abstract][Full Text] [Related]
33. Uncovering a membrane-distal conformation of KRAS available to recruit RAF to the plasma membrane.
Van QN; López CA; Tonelli M; Taylor T; Niu B; Stanley CB; Bhowmik D; Tran TH; Frank PH; Messing S; Alexander P; Scott D; Ye X; Drew M; Chertov O; Lösche M; Ramanathan A; Gross ML; Hengartner NW; Westler WM; Markley JL; Simanshu DK; Nissley DV; Gillette WK; Esposito D; McCormick F; Gnanakaran S; Heinrich F; Stephen AG
Proc Natl Acad Sci U S A; 2020 Sep; 117(39):24258-24268. PubMed ID: 32913056
[TBL] [Abstract][Full Text] [Related]
34. Methylation and proteolysis are essential for efficient membrane binding of prenylated p21K-ras(B).
Hancock JF; Cadwallader K; Marshall CJ
EMBO J; 1991 Mar; 10(3):641-6. PubMed ID: 2001678
[TBL] [Abstract][Full Text] [Related]
35. KARATE: PKA-induced KRAS4B-RHOA-mTORC2 supercomplex phosphorylates AKT in insulin signaling and glucose homeostasis.
Senoo H; Murata D; Wai M; Arai K; Iwata W; Sesaki H; Iijima M
Mol Cell; 2021 Nov; 81(22):4622-4634.e8. PubMed ID: 34551282
[TBL] [Abstract][Full Text] [Related]
36. Allosteric KRas4B Can Modulate SOS1 Fast and Slow Ras Activation Cycles.
Liao TJ; Jang H; Fushman D; Nussinov R
Biophys J; 2018 Aug; 115(4):629-641. PubMed ID: 30097175
[TBL] [Abstract][Full Text] [Related]
37. Mammalian Ras interacts directly with the serine/threonine kinase Raf.
Vojtek AB; Hollenberg SM; Cooper JA
Cell; 1993 Jul; 74(1):205-14. PubMed ID: 8334704
[TBL] [Abstract][Full Text] [Related]
38. Long-lasting Salt Bridges Provide the Anchoring Mechanism of Oncogenic Kirsten Rat Sarcoma Proteins at Cell Membranes.
Lu H; Martí J
J Phys Chem Lett; 2020 Nov; 11(22):9938-9945. PubMed ID: 33170712
[TBL] [Abstract][Full Text] [Related]
39. Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane.
Leevers SJ; Paterson HF; Marshall CJ
Nature; 1994 Jun; 369(6479):411-4. PubMed ID: 8196769
[TBL] [Abstract][Full Text] [Related]
40. High affinity for farnesyltransferase and alternative prenylation contribute individually to K-Ras4B resistance to farnesyltransferase inhibitors.
Fiordalisi JJ; Johnson RL; Weinbaum CA; Sakabe K; Chen Z; Casey PJ; Cox AD
J Biol Chem; 2003 Oct; 278(43):41718-27. PubMed ID: 12882980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
